Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sznol

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Cancer|November 1, 1993
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumorsJ E Janik, M Sznol, W J Urba, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaK Margolin, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1991
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanomaJ P Dutcher, E R Gaynor, D H Boldt, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1995
A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinomaG R Weiss, K A Margolin, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanomaJ A Sparano, R I Fisher, M Sunderland, et al.
Blood|October 1, 1991
Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2aJ W Smith, D L Longo, W J Urba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1993
Dose-related immunologic effects of levamisole in patients with cancerJ Janik, W C Kopp, J W Smith, et al.
Journal of the National Cancer Institute|January 18, 1995
A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2J T Holmund, W C Kopp, R H Wiltrout, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Cancer|November 1, 1993
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumorsJ E Janik, M Sznol, W J Urba, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaK Margolin, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1991
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanomaJ P Dutcher, E R Gaynor, D H Boldt, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1995
A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinomaG R Weiss, K A Margolin, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanomaJ A Sparano, R I Fisher, M Sunderland, et al.
Blood|October 1, 1991
Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2aJ W Smith, D L Longo, W J Urba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1993
Dose-related immunologic effects of levamisole in patients with cancerJ Janik, W C Kopp, J W Smith, et al.
Journal of the National Cancer Institute|January 18, 1995
A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2J T Holmund, W C Kopp, R H Wiltrout, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Pageof 7